Q4 2025 ContextVision AB Earnings Call Transcript
Key Points
- ContextVision AB (LTS:0L8Z) has launched a new series of clinically focused products, enhancing their existing portfolio.
- The company reported early signs of market stabilization in the fourth quarter, indicating potential positive trends moving into 2026.
- ContextVision AB successfully enrolled its first patient in a clinical study, marking a significant milestone in its Data Quality initiative.
- Despite challenging market conditions, the company maintained a solid cash position of SEK69.8 million at the end of the quarter.
- The company continues to engage with more OEMs, opening up new strategic discussions and opportunities in the clinically focused environment.
- Revenue for the fourth quarter declined by 7.3% compared to the same quarter last year, primarily due to negative currency exchange impacts.
- Full-year revenue decreased to SEK110.3 million from SEK130.7 million the previous year, driven by lower license sales and FX effects.
- Adjusted EBITDA for the fourth quarter fell by 30.9% compared to last year, with the margin dropping from 33.4% to 24.9%.
- The company faced a one-time restructuring cost of SEK2.2 million related to changes in its sales and marketing department.
- Negative cash flow for the full year amounted to SEK4.5 million, influenced by lower revenues, increased R&D investments, and a share buyback program.
Welcome to ContextVision. Welcome to the fourth-quarter and full-year 2025 report, today, with Richard Hallström, our CFO; and, myself, Gerald.
The transformation of ContextVision is in full swing. We're combining Image Quality and Data Quality into a quantitative imaging business.
Our fourth quarter saw early signs of stabilization in the market but also in our business. We have enrolled our first patient in a clinical study to collect data and test our new Data Quality products.
We have launched a new series of clinical products at RSNA 2025 back in November in Chicago.
If we look to our financial results, the fourth quarter came in at SEK31.7 million. If we exclude [valuta] impacts, this is a minor growth and rolls up to SEK110.3 million for the year so quite a positive development in the last quarter that we've seen.
Likewise, our margins, 24.9%, for the fourth quarter are recovering.
If we look to earnings per share, we closed the year with a [black zero] despite changes that we made
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
